Study Of GW679769 In Major Depressive Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

356

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

September 30, 2006

Study Completion Date

September 30, 2006

Conditions
Depressive Disorder, MajorMajor Depressive Disorder (MDD)
Interventions
DRUG

GW679769

Trial Locations (31)

10021

GSK Investigational Site, New York

10024

GSK Investigational Site, New York

11235

GSK Investigational Site, Brooklyn

20852

GSK Investigational Site, Rockville

30060

GSK Investigational Site, Marietta

30080

GSK Investigational Site, Smyrna

32789

GSK Investigational Site, Winter Park

32806

GSK Investigational Site, Orlando

33125

GSK Investigational Site, Miami

33161

GSK Investigational Site, North Miami

33301

GSK Investigational Site, Fort Lauderdale

38119

GSK Investigational Site, Memphis

44122

GSK Investigational Site, Beachwood

48336

GSK Investigational Site, Farmington Hills

60181

GSK Investigational Site, Oakbrook Terrace

63301

GSK Investigational Site, Saint Charles

71104

GSK Investigational Site, Shreveport

72223

GSK Investigational Site, Little Rock

75039

GSK Investigational Site, Irving

77566

GSK Investigational Site, Lake Jackson

78756

GSK Investigational Site, Austin

85251

GSK Investigational Site, Scottsdale

90210

GSK Investigational Site, Beverly Hills

97209

GSK Investigational Site, Portland

97401

GSK Investigational Site, Eugene

98004

GSK Investigational Site, Bellevue

08021

GSK Investigational Site, Clementon

T6L 5X8

GSK Investigational Site, Edmonton

E1V 3G5

GSK Investigational Site, Miramichi

L5M 4N4

GSK Investigational Site, Mississauga

J1H 4J6

GSK Investigational Site, Sherbrooke

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY